Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solana Company filings document a Delaware issuer with Nasdaq-listed Class A common stock and a business profile that includes a Solana (SOL) digital asset treasury following its history as Helius Medical Technologies. Recent 8-K reports cover operating results, staking-reward revenue, digital-asset fair value effects, capital actions, registered-direct equity financing, put-option arrangements, and outstanding common stock and pre-funded warrants.
Governance filings include director and officer changes, separation and employment arrangements, board composition, and definitive proxy materials for annual-meeting matters, executive compensation, equity awards, and shareholder voting items. The filings also describe the company’s expansion from its medical-device neurotechnology legacy into SOL holdings, staking, custody, and related infrastructure initiatives.
Solana Company filed a Form 12b-25 (NT 10-Q), stating it cannot file its Q3 2025 Form 10-Q without unreasonable effort or expense. The company plans to file on or before the fifth calendar day following the prescribed due date.
The delay follows the resignation of Baker Tilly US, LLP as independent auditor effective October 15, 2025, and the appointment of CBIZ CPAs P.C. the same day. The company also anticipates significant changes in results for the quarter tied to its PIPE Offerings and adoption of a Solana‑centric Digital Asset Treasury, but it cannot currently quantify the impact.
Solana Company filed a Form 12b-25 (NT 10-Q), stating it cannot file its Q3 2025 Form 10-Q without unreasonable effort or expense. The company plans to file on or before the fifth calendar day following the prescribed due date.
The delay follows the resignation of Baker Tilly US, LLP as independent auditor effective October 15, 2025, and the appointment of CBIZ CPAs P.C. the same day. The company also anticipates significant changes in results for the quarter tied to its PIPE Offerings and adoption of a Solana‑centric Digital Asset Treasury, but it cannot currently quantify the impact.
Solana Company (HSDT) authorized a stock repurchase program of up to $100 million of its Class A common stock. Repurchases may occur in the open market, privately negotiated transactions, block trades, accelerated share repurchases, Rule 10b5-1 trading plans, tender offers, or combinations thereof, and can be conducted in Rule 10b-18 compliant transactions. The company has no obligation to repurchase any shares and may modify, suspend, or discontinue the plan at any time.
At a special meeting on October 30, 2025, shareholders approved the election of Cosmo Jiang to the Board, and he joined the Board immediately after the meeting. On the same day, Jeffrey S. Mathiesen resigned from the Board; his resignation was not due to any disagreement and coincided with Jiang’s election. Separately, Solana Company (Hong Kong) Limited entered into an Employment Agreement with Joseph Chee effective October 30, 2025.
Solana Company (HSDT) furnished a Form 8-K under Item 7.01 to share investor materials. On November 3, 2025, the company posted an Investor Update to its website and issued a press release. These materials are attached as Exhibit 99.1 (Corporate Presentation, dated November 2025) and Exhibit 99.2 (Press Release, dated November 3, 2025) and are incorporated by reference in the 8-K.
The company states the information is furnished pursuant to Regulation FD and not deemed “filed” for purposes of Section 18 of the Exchange Act. Solana Company, formerly Helius Medical Technologies, Inc., lists its Class A Common Stock under the ticker HSDT on The Nasdaq Stock Market LLC.
Solana Co (HSDT) reported a new director appointment disclosure. Director Cosmo Jiang filed a Form 3, the initial statement of beneficial ownership, with an event date of 10/30/2025. The filing indicates no securities are beneficially owned by the reporting person at this time. It is a single‑filer submission and reflects the director relationship only, without listing any non-derivative or derivative holdings.
Solana Company (HSDT) reported the results of its October 30, 2025 special meeting. Stockholders elected Cosmo Jiang to the board and approved share issuances tied to previously issued warrants under Nasdaq Listing Rule 5635(a). They also increased the share pool under the 2022 Equity Incentive Plan by 4,000,000 shares and authorized potential adjournments.
- Quorum: 21,742,341 shares represented; 40,299,220 shares outstanding and entitled to vote as of September 26, 2025.
- Director: For 21,737,666; Withheld 4,675.
- Strategic Advisor Warrants (Pantera Capital Management LP; Summer Wisdom Holdings Limited): For 21,577,950; Against 152,144; Abstain 12,247.
- Cryptocurrency Pre‑Funded & Stapled Warrants (SOL consideration): For 20,135,405; Against 151,931; Abstain 1,455,005.
- 2022 Equity Plan increase (4,000,000 shares): For 21,420,874; Against 319,816; Abstain 1,651.
- Adjournment authority: For 21,734,015; Against 7,893; Abstain 433.
Solana Company filed an 8-K under Regulation FD to note a correction to its October 29, 2025 press release. The company clarified that, in the first sentence of the third paragraph, the amount of “SOL” held by the company as of October 29, 2025 had increased by roughly 0.1 million since its last update on October 6, 2025, not 1 million.
The corrected press release is furnished as Exhibit 99.1. The information in this report, including Exhibit 99.1, is furnished under Item 7.01, is not deemed “filed” for Section 18 liability, and is not incorporated by reference into other filings except as expressly stated.
Solana Company filed an 8-K under Regulation FD to note a correction to its October 29, 2025 press release. The company clarified that, in the first sentence of the third paragraph, the amount of “SOL” held by the company as of October 29, 2025 had increased by roughly 0.1 million since its last update on October 6, 2025, not 1 million.
The corrected press release is furnished as Exhibit 99.1. The information in this report, including Exhibit 99.1, is furnished under Item 7.01, is not deemed “filed” for Section 18 liability, and is not incorporated by reference into other filings except as expressly stated.
Solana Company furnished a press release under Item 7.01 (Regulation FD) on October 20, 2025. The release is attached as Exhibit 99.1 and incorporated by reference in this report.
The Item 7.01 information, including Exhibit 99.1, is furnished and not filed, is not subject to Section 18 of the Exchange Act, and will not be incorporated into Securities Act or Exchange Act filings except by specific reference. Solana Company was formerly known as Helius Medical Technologies, Inc., and its Class A Common Stock trades on Nasdaq under HSDT.
Solana Company reported a change in its independent auditor. On October 15, 2025, Baker Tilly US, LLP resigned as the Company’s independent registered public accounting firm, and the Audit Committee approved the appointment of CBIZ CPAs P.C. as auditor for the fiscal year ending December 31, 2025.
Baker Tilly’s audit reports for 2024 and 2023 had an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern. The Company states there were no disagreements and no reportable events with Baker Tilly through October 15, 2025. A confirming letter from Baker Tilly is filed as Exhibit 16.1.
Solana Company (f/k/a Helius Medical Technologies) called a virtual special meeting to vote on five proposals. The agenda includes electing one new director, authorizing share issuances upon exercise of specific warrants under Nasdaq Listing Rule 5635(a), amending the 2022 Equity Incentive Plan to add 4,000,000 shares, and permitting adjournments if needed.
Proposal 2 seeks approval for issuances upon exercise of Strategic Advisor Warrants held by Pantera Capital Management LP and Summer Wisdom Holdings Limited. Proposal 3 seeks approval for issuances upon exercise of Cryptocurrency Pre-Funded and Cryptocurrency Stapled Warrants issued for consideration in Solana (SOL) cryptocurrency. The Board unanimously recommends voting FOR the director nominee and FOR Proposals 2, 3, 4 and 5.
The meeting is fully virtual, and only stockholders of record as of September 26, 2025 may vote. Shares outstanding were 40,299,220 as of September 26, 2025. The company also disclosed one-time discretionary cash bonuses of $890,000 (CEO) and $610,000 (CFO) under side letters, which will offset any severance or similar cash amounts.
Helius Medical Technologies, Inc. is soliciting proxies for a virtual special meeting to consider five proposals including the election of one director, Nasdaq approvals for issuance of shares on exercise of warrants tied to strategic advisors Pantera Capital and Summer Wisdom and warrants tied to acceptance of Solana (SOL) cryptocurrency, and an amendment to increase available shares under the 2022 Equity Incentive Plan by 4,000,000 shares. The Board unanimously recommends voting FOR the director nominee and Proposals 2–4. The record date is September 26, 2025 and there were 40,299,220 shares outstanding on that date. The filing discloses executive compensation policies, 2024 base salaries and bonus outcomes (Bonuses paid at 83% of target), significant equity grants in 2024 (e.g., options of 808,000 shares to the CEO), and September 24, 2025 side letters providing one-time cash bonuses of $890,000 and $610,000 to the CEO and CFO respectively, offsetting other potential post-transaction payments. The document details committee structure, independence determinations, and insider trading and clawback policies.